Summary
Thermo Fisher Scientific Inc.'s 2017 10-K filing highlights a year of significant growth and strategic expansion, marked by robust revenue increases driven by both organic demand and key acquisitions. The company's mission to 'enable our customers to make the world healthier, cleaner and safer' is supported by a diverse portfolio across four key segments: Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Services. A major event in 2017 was the significant acquisition of Patheon N.V., a move that substantially expanded the company's capabilities in contract development and manufacturing for the pharmaceutical and biotech sectors. Financially, Thermo Fisher demonstrated strong performance with increasing revenues and operating income. The company attributes its growth to increased demand across its end markets, particularly in Asia, alongside successful integration of acquisitions and ongoing productivity improvements. Despite increased investments in growth initiatives and higher amortization costs related to acquisitions, the company maintained healthy operating margins. Looking ahead, Thermo Fisher remains focused on innovation and strategic M&A to maintain its leadership position in serving science.
Financial Highlights
58 data points| Revenue | $20.92B |
| Cost of Revenue | $8.98B |
| Gross Profit | $11.94B |
| R&D Expenses | $887.00M |
| SG&A Expenses | $5.50B |
| Operating Expenses | $17.96B |
| Operating Income | $2.96B |
| Interest Expense | $592.00M |
| Net Income | $2.23B |
| EPS (Basic) | $5.64 |
| EPS (Diluted) | $5.59 |
| Shares Outstanding (Basic) | 395.00M |
| Shares Outstanding (Diluted) | 398.00M |
Key Highlights
- 1Reported consolidated revenues of $20.92 billion, a 14% increase from $18.27 billion in 2016, driven by a $1.63 billion contribution from acquisitions and a 5% organic revenue growth.
- 2Acquired Patheon N.V. in August 2017 for $7.36 billion, significantly expanding its pharmaceutical contract development and manufacturing capabilities.
- 3Total company operating income increased by 21% to $2.97 billion in 2017, with operating income margin improving to 14.2% from 13.4% in 2016.
- 4Life Sciences Solutions and Analytical Instruments segments showed strong revenue growth of 8% and 31% respectively, with Analytical Instruments boosted significantly by acquisitions.
- 5Invested $888 million in research and development in 2017, underscoring a commitment to innovation and new product development.
- 6Company experienced a favorable currency translation effect of $70 million on revenues in 2017.
- 7Ended the year with a strong cash flow from operations of $4.01 billion, supporting strategic initiatives and debt management.